CG Oncology, Inc. Common stock

Day range

$61.06 – $62.80

Open

$61.76

Prev close

$61.71

Volume

880.16K

Market cap

$5.47B

Shares out

88.64M

P/E

—

P/S

878.29

P/B

5.32

P/FCF

—

ROE

-21.8%

ROA

-20.7%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Executive compensation changeMay 26, 2026

  The Company expects to enter into a separation agreement with Mr. Bellete that provides for a general release and waiver of claims against the Company, and pursuant to which Mr. Bellete will receive the severance benefits set forth in Section 4(b) of his Amended and Restated Employment Agreement.

• Executive compensation changeApr 13, 2026

  In connection with his appointment as Chief Financial Officer, the Company and Mr. DeTore entered into an employment agreement, dated April 13, 2026 (the "Employment Agreement"), pursuant to which Mr. DeTore will receive an initial annual base salary of $520,000, less applicable withholdings, and will be eligible for an initial annual target bonus of 45% of his annual base salary. Mr. DeTore will also receive (i) an initial stock option award to purchase shares of the Company's common stock equal to a target value of $4 million... and (ii) a performance stock unit award for the number of shares of the Company's common stock equal to a target value of $1 million.

• Underwriting agreementJan 13, 2026

  The Company filed the Amendment to increase the Shares available to be sold pursuant to the terms of the Sales Agreement by an additional $300,000,000, for an aggregate offering price of up to $550,000,000. The Company previously sold an aggregate of 5,861,984 Shares for gross proceeds of $250,000,000 under the Sales Agreement.

• Business updateJan 9, 2026

  On January 9, 2026, the Company announced an expedited timeline for the topline data readout now expected in the first half of 2026 for the Phase 3 PIVOT-006 clinical trial comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer.

• Director departureNov 26, 2025

  On November 22, 2025, Simone Song submitted her resignation from the Board and all committees on which she served, which resignation was effective immediately. Ms. Song's resignation was not the result of any disagreement with the Company.

Days to cover

8.5

Short interest

10.44M

Avg volume

1.23M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
  neutralZacks Investment Research· Sep 8, 2026
• CG Oncology to Present at Upcoming Investor Conferences in September
  positiveGlobeNewswire Inc.· Sep 2, 2026
• Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
  negativeGlobeNewswire Inc.· Jul 29, 2026
• CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
  positiveGlobeNewswire Inc.· Jul 27, 2026
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
  positiveGlobeNewswire Inc.· May 15, 2026